A phase Ib study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML)
Ottmann, O. G., Fenaux, P., Lübbert, M., DeAngelo, D. J., Garcia-Manero, G., Bhalla, K. N., Sekeres, M. A., Lüdicke, F., Weber, H. J., Winiger, I. J.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article
A phase Ib study of oral panobinostat (LBH589) in combination with cytarabine (ARA-C) and mitoxantrone (MT) as salvage therapy for refractory or relapsed acute myeloid leukemia (AML)
Krauter, J., Ottmann, O. G., Schlenk, R. F., Schaich, M., Bouscary, D., Dombret, H., Lüdicke, F., Weber, H. J., Winiger, I. J.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article